Longitudinal Study of Advanced Non-Small Cell Lung Cancer with Initial Durable Clinical Benefit to Immunotherapy: Strategies for Anti-PD-1/PD-L1 Continuation beyond Progression.
PD-1
acquired resistance
immune checkpoint inhibitors
non-small cell lung cancer
oligoprogression
tumor growth rate
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
26 Nov 2023
26 Nov 2023
Historique:
received:
30
09
2023
revised:
22
11
2023
accepted:
23
11
2023
medline:
9
12
2023
pubmed:
9
12
2023
entrez:
9
12
2023
Statut:
epublish
Résumé
A better understanding of resistance to checkpoint inhibitors is essential to define subsequent treatments in advanced non-small cell lung cancer. By characterizing clinical and radiological features of progression after anti-programmed death-1/programmed death ligand-1 (anti-PD-1/PD-L1), we aimed to define therapeutic strategies in patients with initial durable clinical benefit. This monocentric, retrospective study included patients who presented progressive disease (PD) according to RECIST 1.1 criteria after anti-PD-1/PD-L1 monotherapy. Patients were classified into two groups, "primary resistance" and "Progressive Disease (PD) after Durable Clinical Benefit (DCB)", according to the Society of Immunotherapy of Cancer classification. We compared the post-progression survival (PPS) of both groups and analyzed the patterns of progression. An exploratory analysis was performed using the tumor growth rate (TGR) to assess the global growth kinetics of cancer and the persistent benefit of immunotherapy beyond PD after DCB. A total of 148 patients were included; 105 of them presented "primary resistance" and 43 "PD after DCB". The median PPS was 5.2 months (95% CI: 2.6-6.5) for primary resistance ( PD after DCB is an independent factor of longer post-progression survival with specific patterns that prompt to contemplate loco-regional treatments. TGR is a promising tool to assess the residual benefit of immunotherapy and justify the continuation of immunotherapy in addition to radiotherapy or surgery.
Sections du résumé
BACKGROUND AND AIM
OBJECTIVE
A better understanding of resistance to checkpoint inhibitors is essential to define subsequent treatments in advanced non-small cell lung cancer. By characterizing clinical and radiological features of progression after anti-programmed death-1/programmed death ligand-1 (anti-PD-1/PD-L1), we aimed to define therapeutic strategies in patients with initial durable clinical benefit.
PATIENTS AND METHODS
METHODS
This monocentric, retrospective study included patients who presented progressive disease (PD) according to RECIST 1.1 criteria after anti-PD-1/PD-L1 monotherapy. Patients were classified into two groups, "primary resistance" and "Progressive Disease (PD) after Durable Clinical Benefit (DCB)", according to the Society of Immunotherapy of Cancer classification. We compared the post-progression survival (PPS) of both groups and analyzed the patterns of progression. An exploratory analysis was performed using the tumor growth rate (TGR) to assess the global growth kinetics of cancer and the persistent benefit of immunotherapy beyond PD after DCB.
RESULTS
RESULTS
A total of 148 patients were included; 105 of them presented "primary resistance" and 43 "PD after DCB". The median PPS was 5.2 months (95% CI: 2.6-6.5) for primary resistance (
CONCLUSIONS
CONCLUSIONS
PD after DCB is an independent factor of longer post-progression survival with specific patterns that prompt to contemplate loco-regional treatments. TGR is a promising tool to assess the residual benefit of immunotherapy and justify the continuation of immunotherapy in addition to radiotherapy or surgery.
Identifiants
pubmed: 38067291
pii: cancers15235587
doi: 10.3390/cancers15235587
pmc: PMC10705796
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
Cancer Sci. 2020 Dec;111(12):4442-4452
pubmed: 32770608
Front Oncol. 2021 Jan 19;10:621329
pubmed: 33552993
Curr Oncol. 2019 Feb;26(1):e81-e93
pubmed: 30853813
Ther Adv Med Oncol. 2023 Sep 13;15:17588359231195600
pubmed: 37720494
Cancer Cell. 2016 Aug 8;30(2):243-256
pubmed: 27505671
J Thorac Oncol. 2017 Feb;12(2):179-193
pubmed: 27780780
Cancers (Basel). 2021 Mar 15;13(6):
pubmed: 33803958
Front Oncol. 2022 Jan 25;12:766066
pubmed: 35145913
Clin Cancer Res. 2017 Apr 15;23(8):1920-1928
pubmed: 27827313
N Engl J Med. 2015 Jul 9;373(2):123-35
pubmed: 26028407
N Engl J Med. 2017 Jun 22;376(25):2415-2426
pubmed: 28636851
Clin Cancer Res. 2022 Sep 1;28(17):3797-3803
pubmed: 35767426
Diagnostics (Basel). 2023 Apr 29;13(9):
pubmed: 37174988
Sci Rep. 2021 Jan 28;11(1):2514
pubmed: 33510255
Br J Cancer. 2019 Jan;120(1):3-5
pubmed: 30413824
Cancer. 2015 Aug 1;121(15):2562-9
pubmed: 25891153
Clin Transl Oncol. 2021 Nov;23(11):2237-2252
pubmed: 34002348
Sci Rep. 2022 Feb 28;12(1):3278
pubmed: 35228603
Clin Cancer Res. 2014 Jan 1;20(1):246-52
pubmed: 24240109
Cell. 2017 Sep 7;170(6):1120-1133.e17
pubmed: 28803728
Curr Opin Immunol. 2021 Apr;69:47-55
pubmed: 33676271
Transl Lung Cancer Res. 2022 Jun;11(6):1027-1037
pubmed: 35832458
J Thorac Oncol. 2018 Jun;13(6):831-839
pubmed: 29578107
Ann Oncol. 2021 Dec;32(12):1597-1607
pubmed: 34487855
ERJ Open Res. 2019 Dec 16;5(4):
pubmed: 31857994
J Immunother Cancer. 2020 Mar;8(1):
pubmed: 32238470
J Thorac Dis. 2018 Aug;10(Suppl 21):S2537-S2544
pubmed: 30206497
Nat Rev Cancer. 2019 Jan;19(1):9-31
pubmed: 30532012
Oncotarget. 2017 Dec 15;9(4):4375-4384
pubmed: 29435109
BMC Cancer. 2021 Apr 1;21(1):346
pubmed: 33794809
J Thorac Oncol. 2019 Mar;14(3):328-331
pubmed: 30782378
N Engl J Med. 2015 Oct 22;373(17):1627-39
pubmed: 26412456
J Biomed Inform. 2019 Jul;95:103208
pubmed: 31078660
Science. 2017 Dec 1;358(6367):
pubmed: 29191879
BMC Cancer. 2021 Apr 17;21(1):425
pubmed: 33865350
Cancers (Basel). 2020 Dec 20;12(12):
pubmed: 33419311
J Clin Oncol. 2019 Jun 20;37(18):1558-1565
pubmed: 31067138
J Thorac Oncol. 2019 Dec;14(12):2109-2119
pubmed: 31398540